These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 27751534)
1. LRRK2 and the new era of Parkinson's disease research. The Lancet Neurology Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534 [No Abstract] [Full Text] [Related]
2. LARGE-PD: Examining the genetics of Parkinson's disease in Latin America. Zabetian CP; Mata IF; Mov Disord; 2017 Sep; 32(9):1330-1331. PubMed ID: 28657124 [No Abstract] [Full Text] [Related]
3. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease. Sanjari Moghaddam H; Aarabi MH Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792 [No Abstract] [Full Text] [Related]
4. Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease. Xiao B; Deng X; Ng EY; Allen JC; Lim SY; Ahmad-Annuar A; Tan EK JAMA Neurol; 2018 Jan; 75(1):127-128. PubMed ID: 29131875 [TBL] [Abstract][Full Text] [Related]
5. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease. Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388 [No Abstract] [Full Text] [Related]
10. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease. Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961 [No Abstract] [Full Text] [Related]
11. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Elbaz A Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536 [No Abstract] [Full Text] [Related]
15. Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Wang L; Heckman MG; Aasly JO; Annesi G; Bozi M; Chung SJ; Clarke C; Crosiers D; Eckstein G; Garraux G; Hadjigeorgiou GM; Hattori N; Jeon B; Kim YJ; Kubo M; Lesage S; Lin JJ; Lynch T; Lichtner P; Mellick GD; Mok V; Morrison KE; Quattrone A; Satake W; Silburn PA; Stefanis L; Stockton JD; Tan EK; Toda T; Brice A; Van Broeckhoven C; Uitti RJ; Wirdefeldt K; Wszolek Z; Xiromerisiou G; Maraganore DM; Gasser T; Krüger R; Farrer MJ; Ross OA; Sharma M; Neurobiol Aging; 2017 Jan; 49():217.e1-217.e4. PubMed ID: 27814993 [TBL] [Abstract][Full Text] [Related]
16. Generation of 2 induced pluripotent stem cell lines derived from patients with Parkinson's disease carrying LRRK2 G2385R variant. Cheng YC; Huang CY; Ho MC; Hsu YH; Syu SH; Lu HE; Lin HI; Lin CH; Hsieh PCH Stem Cell Res; 2018 Apr; 28():1-5. PubMed ID: 29414410 [TBL] [Abstract][Full Text] [Related]
17. [Parkinson's disease associated to mutation of the LRRK2 gene, mimicking multisystemic atrophy due to the combination of parkinsonism, early-onset dysautonomia and normal cardiac scintigraphy]. Vilas D; Muxi A; Tolosa E; Compta Y Rev Neurol; 2016 Jul; 63(2):95-6. PubMed ID: 27377986 [No Abstract] [Full Text] [Related]
18. Genetic causes of PD: A pathway to disease modification. Toffoli M; Vieira SRL; Schapira AHV Neuropharmacology; 2020 Jun; 170():108022. PubMed ID: 32119885 [TBL] [Abstract][Full Text] [Related]
19. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations. Grisanti S; Ferri L; Cavallieri F; Fioravanti V; Vincenzi C; Toschi G; Grisendi I; Sabadini R; Paul JJ; Bauer P; Zedde M; Valzania F Mov Disord; 2022 May; 37(5):1117-1118. PubMed ID: 35587629 [No Abstract] [Full Text] [Related]